Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring

AIMS/INTRODUCTION: To assess the effects of sodium glucose co-transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes. MATERIALS AND METHODS: We administered ipragliflozin to 21 inpatients with type 2 diabetes for 7 days, and analyzed the diurnal profiles of plasma glucose and 3-hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kentaro, Nakayama, Hitomi, Yoshinobu, Satoko, Kawano, Seiko, Tsuruta, Munehisa, Nohara, Masayuki, Hasuo, Rika, Akasu, Shoko, Tokubuchi, Ichiro, Wada, Nobuhiko, Hirao, Saori, Iwata, Shinpei, Kaku, Hiroo, Tajiri, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627548/
https://www.ncbi.nlm.nih.gov/pubmed/26543545
http://dx.doi.org/10.1111/jdi.12370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627548/
https://www.ncbi.nlm.nih.gov/pubmed/26543545
http://dx.doi.org/10.1111/jdi.12370

Ejemplares similares